Taghi Kimyai-Asadi, MD
Neurology · Washington, DCNPI 1154328615
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 29.3% of the total. Reporting peaked in 2019 at $621 and has fallen 94.6% since, to $33 in 2025.
Across 132 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$698
- Biogen$280
- Novartis$246
- Eisai Inc.$161
- AbbVie$149
- Supernus Pharmaceuticals, Inc.$108
- plus $736 from 19 others
What the payments were for
- Food & beverage$2,380100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 37 | $698 |
| Biogen | 18 | $280 |
| Novartis | 14 | $246 |
| Eisai Inc. | 8 | $161 |
| AbbVie(2 entities) | 8 | $149 |
| Supernus Pharmaceuticals, Inc. | 6 | $108 |
| Teva Pharmaceuticals USA, Inc. | 6 | $91 |
| Lilly USA, LLC | 4 | $82 |
| EMD Serono, Inc. | 4 | $68 |
| Neurelis, Inc. | 3 | $60 |
| Avanir Pharmaceuticals, Inc. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| Vertical Pharmaceuticals, LLC | 2 | $43 |
| Lundbeck LLC | 2 | $38 |
| SK Life Science, Inc. | 1 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Sanofi | 2 | $30 |
| Pfizer | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
| UCB, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$2,380 in reported general payments places this provider in the 60th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 13 | $137,402 |
| AptiomEslicarbazepine Acetate | 26 | $43,326 |
| ViibrydVilazodone Hcl | 24 | $8,399 |
| Levetiracetam | 235 | $7,669 |
| Gabapentin | 282 | $5,161 |
| Vilazodone Hcl | 22 | $4,675 |
| Memantine Hcl ErMemantine Hcl | 37 | $4,153 |
| Lacosamide | 11 | $3,646 |
| Oxcarbazepine | 47 | $3,403 |
| Donepezil Hcl | 101 | $2,342 |
| Diclofenac Sodium | 24 | $1,870 |
| AmantadineAmantadine Hcl | 25 | $1,699 |
| Pregabalin | 44 | $1,553 |
| Phenytoin Sodium Extended | 39 | $1,388 |
| Carbamazepine | 15 | $1,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $68 | $137,40213 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $698 | $43,32626 claims |
| AbbVieViibryd | $149 | $8,39924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 113 neurology providers in District of Columbia.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.